Dae Seog Heo

Research interests

Publications

• Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody

  Cancer Immunology Immunotherapy · 2017 · 10.1007/s00262-017-2092-x

• Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2016.71.9096

• Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration

  Clinical Cancer Research · 2016 · 10.1158/1078-0432.ccr-15-2834

• Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

  Annals of Oncology · 2016 · 10.1093/annonc/mdw559

• Mechanisms of Acquired Resistance to AZD9291

  Journal of Thoracic Oncology · 2015 · 10.1097/jto.0000000000000688

• Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer

  Journal of Thoracic Oncology · 2013 · 10.1097/jto.0b013e318283dcc0

• Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma

  Cancer · 2012 · 10.1002/cncr.27855

• Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2011.40.9433

• Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

  The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(12)70087-6

• Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis

  Breast Cancer Research · 2011 · 10.1186/bcr2834

• MicroRNA-146a Downregulates NFκB Activity via Targeting TRAF6 and Functions as a Tumor Suppressor Having Strong Prognostic Implications in NK/T Cell Lymphoma

  Clinical Cancer Research · 2011 · 10.1158/1078-0432.ccr-11-0494

• Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2011.35.0660

• Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group

  Annals of Oncology · 2008 · 10.1093/annonc/mdn147

• Palliative chemotherapy for pulmonary pleomorphic carcinoma

  Lung Cancer · 2007 · 10.1016/j.lungcan.2007.05.006

• Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2007.10.8134

• Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation

  Clinical Cancer Research · 2006 · 10.1158/1078-0432.ccr-05-2845

• Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.01.388

• Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type

  Blood · 2005 · 10.1182/blood-2005-05-2056

• Elevated TGF-β1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients

  The Journal of Immunology · 2004 · 10.4049/jimmunol.172.12.7335

• Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies

  Clinical Cancer Research · 2004 · https://doi.org/10.1158/1078-0432.ccr-03-0655

• Validation of the Korean version of the EORTC QLQ-C30

  Quality of Life Research · 2004 · 10.1023/b:qure.0000021692.81214.70

• The Attitudes of Cancer Patients and Their Families Toward the Disclosure of Terminal Illness

  Journal of Clinical Oncology · 2004 · 10.1200/jco.2004.07.053

• A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

  Cancer · 1993 · 10.1002/1097-0142(19930615)71:12<3813::aid-cncr2820711205>3.0.co;2-5

• Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity.

  PubMed · 1990

• Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines.

  PubMed · 1989

Current projects

No projects listed.